Loading...

SNGX SOLIGENIX INC Capital Structure Changes 8-K Filing

SLGN

SNGX

SOLIGENIX INC

(SNGX)

2024 8-K

Compliance Regained

Funding Announcement

FDA Grants Designation

Nasdaq Non-Compliance

Product Expansion

Bylaw Amendment

Loan Termination

Stock Sale Agreement

Warrant Inducement Agreement

Reverse Stock Split

Annual Meeting Adjournment

Compliance with NASDAQ Requ...

Delisting Notice

Annual Meeting of Stockholders

Meeting Adjournment

Annual Meeting Adjournment

Adjournment of Annual Meeti...

Accounting Firm Change

Securities Purchase Agreeme...

Director Compensation Polic...

Investment Agreement

Loan Agreement Amendment

External Links:

Soligenix, Inc. has entered into a Sales Agreement with A.G.P./Alliance Global Partners to sell up to $5.8 million of its common stock at market prices, with the option to set sale parameters and no obligation to sell any shares.

AI Assistant

SOLIGENIX INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.